19P - Curcumin oleoresin inhibits cell growth and migratory properties of breast cancer cells through inhibition of NF-kB pathway

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Basic Science
Breast Cancer
Presenter amir Avan
Citation Annals of Oncology (2016) 27 (suppl_9): ix1-ix8. 10.1093/annonc/mdw573
Authors S. Shahidsales1, Z. Bahmani2, F. Ghasemi3, S.M. Hassanian4, A. Sahebkar5, A. Avan6
  • 1Cancer Research Center, Mashhad University of Medical Sciences-Omid Hospital Cancer Research Center, 000000000 - Mashhad/IR
  • 22) department Of Modern Sciences And Technologies, Mashhad University of Medical Sciences, 000000000 - Mashhad/IR
  • 3Department Of Medical Biotechnology, Mashhad University of Medical Sciences, 0000000000 - Mashhad/IR
  • 43) department Of Medical Biochemistry, Mashhad University of Medical Sciences, 0000000000 - Mashhad/IR
  • 5Biotechnology Research Center, Mashhad University of Medical Sciences, 0000000000 - Mashhad/IR
  • 6Department Of Modern Sciences And Technologies, Mashhad University of Medical Sciences, 000000000 - Mashhad/IR

Abstract

Background

Curcumin is a polyphenolic compound derived from Curcumin longa L. There is growing body of data showing the antitumor effect of curcumin in different cancers; however, the molecular mechanism underlying of this inhibition in breast cancer is still remained to be elucidated. Here we investigated the antitumor activity of curcumin alone or in combination with paclitaxel or doxorubicin in MCF-7 cells in monolayer cell cultures and spheroids models. Moreover, the cytotoxic activity of three different forms of curcumin (phytosomal), phospholipidated curcumin, amorphous curcumin and turmeric oleoresin were evaluated, compared to unformulated curcumin.

Methods

The antiproliferative activity of 4 different forms of curcumin was assessed in monolayer and spheroid models of MCF-7 cells. The cell cycle modulation and migratory behaviors of the cells were determined by FACS and migration assay before and after treatment with curcumin. The expression levels of survivin, CyclinD1, MMP3, MMP9, P65, P21, Nf-kB, and E-cadherin were studied by quantitative RT–PCR and/or western blot.

Results

Ccurcumin suppressed cell growth in MCF-7 cells at 110uM IC50 value. The median drug-effect analysis showed a slight-to-moderate synergism with CI values of 0.8. Curcumin was able to reduce the invasiveness of MCF-7, compared to control cells. Moreover, curcumin inhibited the tumor growth in MCF-7 cells, although this inhibition was more pronounced with amorphous/phospholipidated curcumin. Additionally, curcumin significantly (P 

Conclusions

We demonstrated the antitumor activity of curcumin and its curcumin oleoresin in a breast cancer cell line, supporting further investigations on the therapeutic potential of this novel anticancer agent in in vivo models.

Clinical trial indentification

Legal entity responsible for the study

N/A

Funding

Mashhad University of Medical Sciences

Disclosure

All authors have declared no conflicts of interest.